Dual immunotherapy: Experience in Mesothelioma

Prof. Dr. Paul Baas the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/AVL), the Netherlands

Prof. Baas discusses a 72 year old male patient diagnosed with mesenchymal mesothelioma. He discusses his approach to managing this patient, including efficacy parameters, as well as management of hepatotoxicity, which was experienced by this patient during treatment.

ONC-BE-2100170

S. Peters et al.; Annals of Oncology 2022 (https://doi.org/10.1016/j.annonc.2022.01.074) manuscript published since webinar dd 10Nov2021.

Dual immunotherapy: Experience in mNSCLC

Prof. Dr. Luis Paz-Ares Hospital Universitario de Madrid, Spain

Prof. Paz-Ares discusses a 60 year old male patient diagnosed with metastatic NSCLC. He discusses his approach to managing this patient, including efficacy parameters, as well as management of nephritis and diarrhea, which was experienced by this patient during treatment.

ONC-BE-2100170

Reck et al.; ESMO open 2021 (https://doi.org/10.1016/j.esmoop.2021.100273) manuscript published since webinar dd 10Nov2021.

Meet-the-Expert:

Interactive Panel Discussion

Topics discussed by Prof Baas and Prof Paz-Ares included rationale for treatment regimen in CM-743, quality of life on particular arms in CM-743 for patients with uMPM, treatment discontinuation after irAEs as well as re-challenge, managing patients with brain metastases and use of immunosuppressants with immunotherapy for safety management.